286 related articles for article (PubMed ID: 24572789)
41. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
42. IL-15/sIL-15Rα gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys.
Sun H; Liu D
Cancer Gene Ther; 2016; 23(2-3):54-60. PubMed ID: 26742578
[TBL] [Abstract][Full Text] [Related]
43. Selective reduction of post-selection CD8 thymocyte proliferation in IL-15Rα deficient mice.
Chow KP; Qiu JT; Lee JM; Hsu SL; Yang SC; Wu NN; Huang W; Wu TS
PLoS One; 2012; 7(3):e33152. PubMed ID: 22448237
[TBL] [Abstract][Full Text] [Related]
44. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
[TBL] [Abstract][Full Text] [Related]
45. IRF-1 promotes liver transplant ischemia/reperfusion injury via hepatocyte IL-15/IL-15Rα production.
Yokota S; Yoshida O; Dou L; Spadaro AV; Isse K; Ross MA; Stolz DB; Kimura S; Du Q; Demetris AJ; Thomson AW; Geller DA
J Immunol; 2015 Jun; 194(12):6045-56. PubMed ID: 25964490
[TBL] [Abstract][Full Text] [Related]
46. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
47.
Anton OM; Peterson ME; Hollander MJ; Dorward DW; Arora G; Traba J; Rajagopalan S; Snapp EL; Garcia KC; Waldmann TA; Long EO
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):522-531. PubMed ID: 31871169
[TBL] [Abstract][Full Text] [Related]
48. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
49. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
50. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer.
Badoual C; Bouchaud G; Agueznay Nel H; Mortier E; Hans S; Gey A; Fernani F; Peyrard S; -Puig PL; Bruneval P; Sastre X; Plet A; Garrigue-Antar L; Quintin-Colonna F; Fridman WH; Brasnu D; Jacques Y; Tartour E
Cancer Res; 2008 May; 68(10):3907-14. PubMed ID: 18483276
[TBL] [Abstract][Full Text] [Related]
51. A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
[TBL] [Abstract][Full Text] [Related]
52. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells.
Sato N; Patel HJ; Waldmann TA; Tagaya Y
Proc Natl Acad Sci U S A; 2007 Jan; 104(2):588-93. PubMed ID: 17202253
[TBL] [Abstract][Full Text] [Related]
53. Tumor cell-expressed IL-15Rα drives antagonistic effects on the progression and immune control of gastric cancer and is epigenetically regulated in EBV-positive gastric cancer.
Wei J; Guo C; An X; Miao W; Zhang C; Wang B; Cai W; Li M; Zhang F
Cell Oncol (Dordr); 2020 Dec; 43(6):1085-1097. PubMed ID: 32767257
[TBL] [Abstract][Full Text] [Related]
54. Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells.
Schluns KS; Klonowski KD; Lefrançois L
Blood; 2004 Feb; 103(3):988-94. PubMed ID: 14512307
[TBL] [Abstract][Full Text] [Related]
55. Molecular cloning and expression analysis of interleukin (IL)-15 and IL-15 receptor α from rock bream, Oplegnathus fasciatus.
Bae JS; Shim SH; Hwang SD; Kim JW; Park DW; Park CI
Fish Shellfish Immunol; 2013 Oct; 35(4):1209-15. PubMed ID: 23911652
[TBL] [Abstract][Full Text] [Related]
56. Protective and Therapeutic Effects of an IL-15:IL-15Rα-Secreting Cell-Based Cancer Vaccine Using a Baculovirus System.
Do-Thi VA; Lee H; Jeong HJ; Lee JO; Kim YS
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439192
[TBL] [Abstract][Full Text] [Related]
57. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
58. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
[TBL] [Abstract][Full Text] [Related]
59. Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses.
Rückert R; Brandt K; Bulanova E; Mirghomizadeh F; Paus R; Bulfone-Paus S
Eur J Immunol; 2003 Dec; 33(12):3493-503. PubMed ID: 14635060
[TBL] [Abstract][Full Text] [Related]
60. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.
Nakashima H; Fujisawa T; Husain SR; Puri RK
J Transl Med; 2010 Nov; 8():116. PubMed ID: 21067607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
